Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys

Vaccine

Volumn 28, Issue 43, 2010, Pages 7081-7091

  Zielinski, Rafal J ^a   Smedley, Jeremy V ^a   Perera, Pin Yu ^b   Silvera, Peter M ^c   Waldmann, Thomas A ^a   Capala, Jacek ^a   Perera, Liyanage P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

IL 15; Monkeypox; Smallpox vaccine

Indexed keywords

SMALLPOX VACCINE; UNCLASSIFIED DRUG; WYETH 15 VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; MALE; MONKEY; MONKEYPOX; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE; VIRUS LOAD; VIRUS STRAIN;

ANIMALS; FEMALE; HUMANS; INTERLEUKIN-15; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; MICE, NUDE; MONKEYPOX; NEUTRALIZATION TESTS; SMALLPOX; SMALLPOX VACCINE; VIRAL LOAD;

EID: 77957372036     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.008     Document Type: Article

References (36)

1. Fenner F., Henderson D.A., Arita I., Jecek Z., Ladnyi I.D. Smallpox and its eradication. History of International Public Health 1988, World Health Organization, Geneva, Switzerland.
2. Fenner F. Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign. Res Virol 1989, 140:465-466.
3. Poland G.A., Grabenstein J.D., Neff J.M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005, 23:2078-2081.
4. Lane J.M., Ruben F.L., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968. N Engl J Med 1969, 281(22):1201-1208.
5. Greenberg R.N., Kennedy J.S. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008, 17(4):555-564.
6. Perera L.P., Waldmann T.A., Mosca J.D., Baldwin N., Berzofsky J.A., Oh S.K. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol 2007, 81(16):8774-8783.
7. Alexander W.A., Moss B., Fuerst T.R. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol 1992, 66(5):2934-2942.
8. Kennedy J.S., Greenberg R.N. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009, 8(1):13-24.
9. Midgley C.M., Putz M.M., Weber J.N., Smith G.L. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol 2008, 89(Pt 12):2992-2997.
10. Buller R.M.L., Palumbo GJ Safety and attenuation of vaccinia viruses. Recombinant poxviruses 1992, 235-267. CRC Press, Boca Raton, FL. M.M. Binns, G.L. Smith (Eds.).
11. Hung C.F., Tsai Y.C., He L., Coukos G., Fodor I., Qin L., et al. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther 2007, 14(1):20-29.
12. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006, 6:595-601.
13. Rochman Y., Spolski R., Leonard W.J. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009, 9(7):480-490.
14. Hügin A.W., Flexner C., Moss B. Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responses. Cell Immunol 1993, 152(2):499-509.
15. Perera L.P., Goldman C.K., Waldmann T.A. Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc Natl Acad Sci USA 2001, 98(9):5146-5151.
16. Gronvall G.K., Trent D., Borio L., Brey R., Nagao L. Alliance for biosecurity. The FDA animal efficacy rule and biodefense. Nat Biotechnol 2007, 25(10):1084-1087.
17. HHS New drug and biological drug products; evidence needed demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist 2002, 67(105):37988-37998. Food and Drug Administration.
18. Flexner C., Hügin A., Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 1987, 330(6145):259-262.
19. Ramshaw I.A., Andrew M.E., Phillips S.M., Boyle D.B., Coupar B.E. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 1987, 329(6139):545-546.
20. Flexner C., Moss B., London W.T., Murphy B.R. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine 1990, 8(1):17-21.
21. Ruby J., Brinkman C., Jones S., Ramshaw I. Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2. Immunol Cell Biol 1990, 68(Pt 2):113-117.
22. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428(6979):182-185.
23. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H., et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005, 79(12):7845-7851.
24. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005, 11(7):740-747.
25. Marriott K.A., Parkinson C.V., Morefield S.I., Davenport R., Nichols R., Monath T.P. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. Vaccine 2008, 26(4):581-588.
26. Earl P.L., Americo J.L., Wyatt L.S., Espenshade O., Bassler J., Gong K., et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci USA 2008, 105(31):10889-10894.
27. Shao L., Huang D., Wei H., Wang R.C., Chen C.Y., Shen L., et al. Expansion, reexpansion, and recall-like expansion of Vgamma2Vdelta2 T cells in smallpox vaccination and monkeypox virus infection. J Virol 2009, 83(22):11959-11965.
28. Nigam P., Earl P.L., Americo J.L., Sharma S., Wyatt L.S., Edghill-Spano Y., et al. DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 2007, 366(1):73-83.
29. Oh S., Berzofsky J.A., Burke D.S., Waldmann T.A., Perera L.P. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA 2003, 100(6):3392-3397.
30. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007, 204(6):1405-1416.
31. Amanna I.J., Slifka M.K., Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006, 211:320-337.
32. Taub D.D., Ershler W.B., Janowski M., Artz A., Key M.L., McKelvey J., et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008, 121(12):1058-1064.
33. Saito T., Fujii T., Kanatani Y., Saito M., Morikawa S., Yokote H., et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 2009, 301(10):1025-1033.
34. Prausnitz M.R., Mikszta J.A., Cormier M., Andrianov A.K. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009, 333:369-393.
35. Künzi V., Klap J.M., Seiberling M.K., Herzog C., Hartmann K., Kürsteiner O., et al. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009, 27(27):3561-3567.
36. Liu L., Zhong Q., Tian T., Dubin K., Athale S.K., Kupper T.S., et al. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010, 16(2):224-227.